<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614284</url>
  </required_header>
  <id_info>
    <org_study_id>CP - 2201VLF</org_study_id>
    <nct_id>NCT05614284</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of Virtuous and Autograft in Lumbar Fusion</brief_title>
  <official_title>A Prospective, Post-Market, Multicenter Comparative Analysis of the Efficacy of Virtuous and Autograft Bone Graft in Lumbar Fusion Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthofix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orthofix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the lumbar fusion rates at 12 and 24 months when lumbar arthrodesis is performed&#xD;
      using Virtuous or Autograft Bone Graft. Surgical approach is limited to TLIF (MIS or Open)&#xD;
      with posterior fixation and supplemental posterolateral fusion as directed by physician, but&#xD;
      must comply with FDA approved/cleared indication for use and labeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare clinical and radiographic outcomes in patients&#xD;
      undergoing transforaminal lumbar interbody fusion (minimally invasive or open) with either&#xD;
      Virtuous bone graft or autograft/allograft bone graft.&#xD;
&#xD;
      Compare the lumbar fusion rates at 12 and 24 months when lumbar arthrodesis is performed&#xD;
      using Virtuous or Autograft Bone Graft. Surgical approach is limited to TLIF (MIS or Open)&#xD;
      with posterior fixation and supplemental posterolateral fusion as directed by physician, but&#xD;
      must comply with FDA approved/cleared indication for use and labeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2023</start_date>
  <completion_date type="Anticipated">December 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 Enrollment: Virtuous vs. Autograft</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Fusion</measure>
    <time_frame>Twelve months</time_frame>
    <description>Fusion status at Twelve months postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes</measure>
    <time_frame>Twelve months</time_frame>
    <description>Patient Reported Outcomes (PROM): Disability and Pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>Twelve and Twenty-four months</time_frame>
    <description>Incidence of Adverse Events and Serious Adverse Events through Twelve and Twenty-four months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Virtuous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtuous +/- Local Bone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autograft +/- Allograft Chips</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtuos</intervention_name>
    <description>Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.</description>
    <arm_group_label>Autograft</arm_group_label>
    <arm_group_label>Virtuous</arm_group_label>
    <other_name>Autograft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               1. At least 18 years of age at the time of surgery&#xD;
&#xD;
               2. Undergoing lumbar spine fusion surgery with one of the following bone grafting&#xD;
                  options:&#xD;
&#xD;
                    1. Virtuous&#xD;
&#xD;
                    2. Virtuous with Autograft (local bone)&#xD;
&#xD;
                    3. Autograft&#xD;
&#xD;
                    4. Autograft + allograft (cancellous bone chips)&#xD;
&#xD;
               3. Subject must have a documented diagnosis of DDD. DDD is defined by back and/or&#xD;
                  radicular pain with degeneration of the disc as confirmed by medical history,&#xD;
                  physical examination, and radiographic studies that may include CT, MRI, plain&#xD;
                  X-ray film, discography, myelography, etc. with one or more of the following&#xD;
                  findings:&#xD;
&#xD;
                    1. Instability as defined by &gt;3mm translation or &gt;5 degrees angulation&#xD;
&#xD;
                    2. Osteophyte formation of facet joints or vertebral endplates&#xD;
&#xD;
                    3. Decreased disc height, on average by &gt;2mm, but dependent upon the spinal&#xD;
                       level&#xD;
&#xD;
                    4. Scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint&#xD;
                       capsule&#xD;
&#xD;
                    5. Herniated nucleus pulposus&#xD;
&#xD;
                    6. Facet joint degeneration/changes; and/or&#xD;
&#xD;
                    7. Vacuum phenomenon&#xD;
&#xD;
               4. Subject may have up to a Grade I Spondylolisthesis of the lumbar spine with&#xD;
                  clinical manifestations of one or more of the following phenomena:&#xD;
&#xD;
                    1. Radiculopathy&#xD;
&#xD;
                    2. Sensory deficit&#xD;
&#xD;
                    3. Motor weakness&#xD;
&#xD;
                    4. Reflex changes&#xD;
&#xD;
               5. Subject must require lumbar posterolateral arthrodesis at 1-2 contiguous levels&#xD;
                  (L1-S1).&#xD;
&#xD;
               6. The number of levels decompressed must equal the number of levels fused.&#xD;
&#xD;
               7. Subject must have been unresponsive to conservative care for at least 6 months&#xD;
                  prior to fusion surgery.&#xD;
&#xD;
               8. Subject must agree not to use electromagnetic adjuncts to enhance bone fusion&#xD;
                  during the course of the study&#xD;
&#xD;
               9. Subject must be willing and able to sign an informed consent document.&#xD;
&#xD;
              10. Subject must be willing and able to return for all follow-up visits, agree to&#xD;
                  participate in postoperative clinical and radiographic evaluations and comply&#xD;
                  with the required study regimen.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject is under 18 years of age (&lt;18) at the time of consent&#xD;
&#xD;
          2. Subject has had prior lumbar spine fusion surgery at any level&#xD;
&#xD;
          3. Subject has greater than grade 1 spondylolisthesis of the lumbar spine&#xD;
&#xD;
          4. Subject is currently undergoing treatment for malignancy or has undergone treatment&#xD;
             for malignancy in the past 5 years (benign skin cancer is permitted)&#xD;
&#xD;
          5. Subject is pregnant (confirmed by pregnancy test) or nursing or planning to become&#xD;
             pregnant during the two years (24 months) following arthrodesis&#xD;
&#xD;
          6. Subject has an active local or systemic infection or is undergoing adjunctive&#xD;
             treatment for local or systemic infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Gunter, MPH</last_name>
    <phone>9015962386</phone>
    <email>chrisgunter@orthofix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Michigan Brain and Spine</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramiro De La Torre, MD</last_name>
      <phone>248-898-5000</phone>
      <email>ramiroperez@icloud.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lumbar Fusion</keyword>
  <keyword>Cellular Based Lyograft</keyword>
  <keyword>TLIF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

